Stay updated on Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial
Sign up to get notified when there's something new on the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page.

Latest updates to the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA revision/version string on the ClinicalTrials.gov page was updated from v3.5.2 to v3.5.3, reflecting an interface or backend site release rather than a change to the study information.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check49 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check56 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3. It appears to be a backend/UI update with no visible changes to study details or eligibility.SummaryDifference0.1%

- Check85 days agoChange DetectedThe change consists of Revision: v3.4.2 replacing v3.4.1, which appears to be a metadata/version update without altering study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check92 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1.SummaryDifference0.1%

Stay in the know with updates to Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page.